Global Markets Direct’s, Osteosarcoma – Pipeline Review, H2 2016′, provides an overview of the Osteosarcoma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Osteosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Complete report on Osteosarcoma – Pipeline Review, H2 2016 addition with 37 market data tables and 15 figures, spread across 223 pages is http://www.rnrmarketresearch.com/osteosarcoma-pipeline-review-h2-2016-market-report.html
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis
Drugs Profile Discussed in this Research:
3D-QM, 3D-QMS, ADXS-HER2, aldoxorubicin hydrochloride, AM-7209, AU-101, AV-203, axitinib, cabozantinib s-malate, Cellular Immunotherapy for GD2 Expressing Solid Tumors, Cellular Immunotherapy to Target HER2 for Glioblastoma Multiforme and Osteosarcoma, Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology, celyvir, CGS-200, cisplatin SR, dihydroartemisinin, dinutuximab, everolimus ,glembatumumab vedotin,irinotecan hydrochloride,ligerin ,LLL-12,Modufolin,Monoclonal Antibody for Osteosarcoma ,Monoclonal Antibody to Inhibit GD2 for Oncology ,Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastoma and Osteosarcoma,MPE-8.3 ,NP-137 ,OBP-702,Oligonucleotides to Inhibit Thymidylate Synthase and Dihydrofolate Reductase for Osteosarcoma and Colon Cancer, pazopanib hydrochloride , pembrolizumab , Peptide to Target COX-2 and MAS-GPCR for Oncology, radium Ra 223 dichloride, RSF-101 , S-588410, SEN-461, Small Molecules to Agonize Vitamin D3 Receptor for Osteosarcoma, Small Molecules to Inhibit CaMKII for Osteosarcoma, T-2GES, Vaccine for Osteosarcoma
Advaxis, Inc, Amgen Inc., AVEO Pharmaceuticals, Inc., Bayer AG, Bellicum Pharmaceuticals, Inc., Celldex Therapeutics, Inc., CytRx Corporation, Eleison Pharmaceuticals LLC, Exelixis, Inc., Isofol Medical AB, MediaPharma s.r.l., Merck & Co., Inc,Merrimack Pharmaceuticals, Inc., Netris Pharma S.A.S., Novartis AG, Oncolys BioPharma Inc, Pfizer Inc., Shionogi & Co., Ltd., Teijin Pharma Limited, United Therapeutics Corporation,
Inquire before buying for this reporthttp://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=692215(This is a premium report price at US$2000 for a single user PDF license).
The report provides a snapshot of the global therapeutic landscape of Osteosarcoma
The report reviews pipeline therapeutics for Osteosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved Osteosarcoma therapeutics and enlists all their major and minor projects
The report assesses Osteosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news related to pipeline therapeutics for Osteosarcoma
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for Osteosarcoma
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Osteosarcoma pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.